DelMar Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.07.19	6 Top Gainers In Healthcare Sector (GHDX, THC, IART…) (RTTNews)
22.05.19	5 Top Gainers In Pharma Sector (ARRY, EQ, ARWR...) (RTTNews)
22.05.18	DelMar Appoints Saiid Zarrabian to Full-Time President and CEO (PR Newswire)
17.05.18	DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results (PR Newswire)
02.05.18	CollabNet VersionOne recognized by Forrester Research for Providing Agile ALM plus DevOps solutions for Value Stream Mapping (PR Newswire)
17.04.18	DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM (PR Newswire)
16.04.18	DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research (PR Newswire)
27.03.18	UNITY Biotechnology, Inc. Appoints Pharmaceutical Industry Executive Paul L. Berns to Board of Directors (PR Newswire)
28.02.18	TTOO Gains Steam, LPCN Up On Upgrade, ALDX Abuzz (RTTNews)
14.02.18	DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results (PR Newswire)
26.12.17	DelMar Announces Fast Track Designation For VAL-083 In Recurrent Glioblastoma (RTTNews)
26.12.17	DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma (PR Newswire)
05.12.17	Growth, Success, and Community Involvement Leads to Ensunet's Selection as 2017 Small Business of the Year! (PR Newswire)
22.11.17	First 2-drug HIV Regimen Gets FDA Nod, Starpharma Shines, ARDX Drops RDX7675 (RTTNews)
21.11.17	DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting (PR Newswire)
14.11.17	DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results (PR Newswire)
07.11.17	DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer (PR Newswire)
31.10.17	DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer (PR Newswire)
26.10.17	Pura Naturals Strengthens its Communications and Marketing Strategy through the Engagement of Three Strategic Partners (PR Newswire)
09.10.17	ImaginAb Closes $8 million New Funding to Accelerate Clinical Development of CD8 ImmunoPET Agent (PR Newswire)
03.10.17	DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer (PR Newswire)
29.09.17	DelMar Pharmaceuticals Announces Fiscal Year 2017 Financial Results (PR Newswire)
27.09.17	DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer (PR Newswire)
20.09.17	DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083 (PR Newswire)
18.09.17	DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer (PR Newswire)
11.09.17	DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme (PR Newswire)
06.09.17	DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017 (PR Newswire)
26.08.17	Aytu BioScience Announces Reverse Split of its Common Stock (PR Newswire)
24.07.17	DelMar Pharmaceuticals Receives Approval from China's Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM (PR Newswire)
20.07.17	Amgen Announces Webcast of 2017 Second Quarter Financial Results (PR Newswire)
18.07.17	DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM (PR Newswire)
11.07.17	DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and Names Dr. Erich Mohr as Chairman (PR Newswire)
29.06.17	DelMar Pharmaceuticals Joins National Brain Tumor Society's Research Roundtable (PR Newswire)
22.06.17	DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM (PR Newswire)
16.06.17	DelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma ("GBM") at SNO's Pediatric Neuro-Oncology Basic and Translational Research Conference (PR Newswire)
18.05.17	DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results (PR Newswire)
11.05.17	DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM) (PR Newswire)
25.04.17	DelMar Pharmaceuticals Collaborates with Duke University to Explore VAL-083 as a Front-Line Treatment for Glioblastoma Multiforme (PR Newswire)
21.04.17	DelMar Pharmaceuticals Announces Closing Of $9,000,000 Public Offering Of Common Stock And Warrants (PR Newswire)
18.04.17	Gainers & Losers Of Apr.17: CBLI, INFI, PBYI, OMED, INCY... (RTTNews)
12.04.17	DelMar Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants (PR Newswire)
05.04.17	DelMar Pharmaceuticals Provides VAL-083 Updates from the Ongoing American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
13.02.17	DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) (PR Newswire)
25.01.17	DelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) (PR Newswire)
20.01.17	Gainers & Losers Of The Day: CATB, MCUR, BIOC, SSH, ZYNE… (RTTNews)
09.01.17	DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from the Government of Canada to Support Expanded Research with Lead Product Candidate VAL-083 (PR Newswire)
14.12.16	DelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu DelMar Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten